Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 1, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 30, 2026 — +31.7% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$920.00 – $940.00Entry zone — fair-value band

$933.83Published — price the day we called it

$1,036.55Target — the price the thesis aimed for

$1,238.00Peak — highest point inside the window, not a realized return

$1,229.93Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 49 days.

At window close

+31.7%

realized, from the publication price to the last close inside the window

Peak gain

+32.6%

peak, from the publication price — not a realized return

S&P 500, same window

+14.3%

SPY over the identical days, dividend-adjusted

Window close

$1,229.93

last close inside the window, ended June 30, 2026

Peak price

$1,238.00

peak on June 29, 2026 — not a realized return

Days to target

The thesis — published April 1, 2026

Predicted growth

+11%

over the measurement window

Target price

$1,036.55

the price the thesis aimed for

Entry zone

$920.00 – $940.00

the fair-value band we waited for

Price at publication

$933.83

published April 1, 2026

Confidence

78%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly is kept high on the short-term list because it mixes steady healthcare demand with ongoing growth. The stock is holding near its trend instead of falling apart, and recent commentary suggests it may be slightly undervalued. Interest in GLP-1 drugs helps the story, but sentiment is already strong, so gains may come gradually rather than in a quick surge.

Primary drivers

Strong sales from diabetes and obesity medicines keep revenue growing
Healthcare stability helps offset market swings
Recent valuation notes suggest shares may be reasonably priced
Company operations and reporting have remained consistent and reliable

How it played out

LLY: target reached in 49 days

Lyra published a short-term thesis at $933.83, with 11% expected growth and a $1,036.55 target. The thesis pointed to sales from diabetes and obesity medicines, steady healthcare demand, valuation notes that viewed the shares as reasonably priced, and consistent company operations. It expected gains to arrive gradually because sentiment was already strong.

The shares reached the target in 49 days. They later peaked at $1,238 on June 29, a 32.6% gain, and ended the window at $1,229.93. The peak was above the target, and the closing price remained above it. The published thesis played out and exceeded its stated price objective.

What happened during the window

On April 30, Lilly reported that first-quarter revenue rose 56% to $19.8 billion and raised its full-year guidance. On June 7, the company announced results from analyses of its Foundayo obesity trials in women at different stages of menopause.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals